Month: September 2026

Pilots across North America, Continental Europe and the UK & Ireland set foundation for rollout in 2027

GREENWICH, Conn., Sept. 23, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced global pilots of a new Labor Management System (LMS) designed to enhance workforce planning capabilities and operating efficiencies.

The pilots, being conducted at sites across the U.S., UK, Netherlands, Poland and Spain, represent an important step toward the creation of a standard single global labor management solution that can be deployed consistently across GXO’s operations worldwide.

“We are continuously looking for new ways to help our sites operate more efficiently while delivering even greater value to our customers,” said Bart Beeks, Chief Operations Officer, GXO. “A single global labor management system is a key lever of The GXO Way, our global operations framework for standardizing and scaling operational excellence. A standardized LMS will support more informed decision-making and help us drive productivity at scale. The pilots are an important milestone in building a consistent, data-driven approach to labor management across our operations worldwide.”

The LMS provides real-time visibility into labor performance and workforce planning, helping site leaders better align resources with customer demand while improving operational efficiency. By providing a common platform and standardized performance framework, the LMS will help accelerate operational improvements while supporting GXO’s growth and profitability objectives.

GXO expects to begin scaling the LMS platform across its network in 2027, as part of its broader strategy to standardize best practices, accelerate continuous improvement and strengthen operational excellence across its global footprint.

About GXO

GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has over 150,000 team members across more than 1,000 facilities, totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.

Media contacts
Matthew Schmidt 
+1 203-307-2809 
matt.schmidt@gxo.com

Kathleen Juviler
+1 203-921-9121
Kathleen.juviler@gxo.com

GREAT NECK, N.Y., Sept. 23, 2026 (GLOBE NEWSWIRE) —

Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on July 28, 2026, a cash dividend of $0.11 per share will be paid to all shareholders of record on October 8, 2026. The dividend will be paid on October 15, 2026.

Contact:
Assaf Ran, CEO
(516) 444-3400
www.linkedin.com/in/assafran
SOURCE: Manhattan Bridge Capital, Inc.

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.

EADV Congress 2026 Presentation Details:

Late-Breaker Oral Presentation:

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of the Phase 2 Placebo Controlled LOTUS Trial
Presenter: Dr. Martina Porter, Assistant Professor of Dermatology at Harvard Medical School and Vice Chair for Research and Academics, Department of Dermatology at Beth Israel Deaconess Medical Center
Location: Hall A
Date: Thursday, October 1, 2026 5:00pm CEST

Poster Presentation:

Title: Efficacy and Safety of Abdakibart, a Selective Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa; Primary Results of the Placebo-Controlled Phase 2 LOTUS Trial
Location: ePoster Area; Inflammatory Skin Diseases – Part II
Date: Wednesday, September 30, 2026 7:00am CEST

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Talisker Resources Ltd. (“Talisker”) (TSX: TSK; OTCQX: TSKFF), a junior resource company involved in the exploration and development of gold projects in British Columbia, has qualified to trade on the OTCQX® Best Market. Talisker upgraded to OTCQX from the OTCQB® Venture Market.

Talisker begins trading today on OTCQX under the symbol “TSKFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

As one of the largest holders of mineral claims in British Columbia, Talisker has successfully made the transition from explorer, developer to gold producer with its first producing gold mine, the Mustang Mine transitioned into production in H2 2025. Talisker plans to develop numerous mining centres over the 40km strike length of the company’s 100% owned Bralorne Gold Project with a view to achieve its corporate vision of 200,000 ounces of annual gold production. With a global resource of 3.45M oz of with an average grade in excess of 8 g/t Talisker presents a real gold mining growth opportunity. 

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Terry Harbort, CEO of Talisker stated, “We are pleased to have re-qualified for trading on the OTCQX Market which we anticipate will provide Talisker with wider visibility to the US investment community.”

Trading in non-U.S. North American securities on OTC Markets reached $23.4 billion in the second quarter of 2026, representing an 88.25% increase over Q2 2025. OTC Markets recorded $453.34 billion in total dollar volume in the first half of the year. Canada ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker’s flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is producing at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an advanced stage project with significant exploration potential from an historical high-grade producing gold mine and the Spences Bridge Project where the Company has a significant landholding in the emerging Spences Bridge Gold Belt, and several other early-stage Greenfields projects.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:

OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001

ORKA-001 maintained a favorable safety and tolerability profile through Week 28

52-week EVERLAST-A data for all patients expected in December 2026

16-week EVERLAST-B data expected in 4Q 2026

MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis.

“These Week 28 results, with responses continuing to deepen months after the last dose, point to the incredible potential of ORKA-001,” said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. “With over 70% of patients achieving completely clear skin after just two induction doses and a safety profile consistent with the IL-23 class, ORKA-001 has the potential to redefine the standard of care for psoriasis. We look forward to sharing the full 52-week data later this year.”

“The depth of clearance seen at Week 28, achieved without any dosing beyond Week 4, is remarkable,” said Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine and lead investigator for EVERLAST-A. “To see PASI 100 rates continue to climb over time speaks to the potential of this molecule. The emerging profile of ORKA-001 could offer patients substantial disease control along with very infrequent dosing.”

EVERLAST-A is a randomized, double-blind, placebo-controlled Phase 2a trial evaluating the safety, efficacy, and pharmacokinetics of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The study is being conducted across 26 sites in the United States and Canada and enrolled 84 patients randomized 3:1 to receive 600 mg of ORKA-001 at Week 0 and 4 or matching placebo. Patients who initially received placebo received 600 mg of ORKA-001 at Week 16 and 20. The study continues through Week 52 to assess durability of response, maintenance dosing, and long-term safety.

Efficacy

As previously reported, 63.5% of patients (40 of 63) treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16. Clinical responses continued to deepen through Week 28, six months after the last dose of ORKA-001. PASI 100 response rates increased to 71.4% (45 of 63) and PASI 90 response rates increased to 87.3% (55 of 63) at Week 28. IGA 0/1 response rates were maintained at 84.1% (53 of 63).

Patients who initially received placebo and crossed over blinded to ORKA-001 at Week 16 demonstrated a similar pattern of clinical response to those initially receiving ORKA-001. In this dosing arm, 40.0% (8 of 20) achieved PASI 100 at Week 28 (12 weeks after dosing) compared to 42.9% (27 of 63) of patients in the active arm at the equivalent timepoint.

Safety

ORKA-001 continues to be well tolerated, with a safety profile consistent with the IL-23p19 class. Between Weeks 16-28, the only treatment-emergent adverse event in ≥5% of patients receiving ORKA-001 was upper respiratory tract infection, occurring in 8% (7 of 83) of patients. Two patients experienced serious adverse events, neither deemed drug related: one tibial fracture and one case of prostate adenocarcinoma in a patient with elevated prostate-specific antigen (PSA) at baseline. There continue to be no injection site reactions. No impact of anti-drug antibodies on safety, efficacy, or PK has been observed.

Upcoming Milestones for ORKA-001 

Oruka plans to share longer-term data from EVERLAST-A, including efficacy at Week 52 for all patients, in December 2026. The Company also continues to advance the EVERLAST-B Phase 2b trial of ORKA-001, with data expected during the fourth quarter of 2026. 

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. 

Forward Looking Statements

Certain statements in this press release, other than statements of historical fact, are “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefits, efficacy, safety, tolerability, durability of response and dosing profile of ORKA-001; the potential for ORKA-001 to provide durable disease control with infrequent dosing; the planned conduct, progress, timing and results of the EVERLAST-A and EVERLAST-B trials; and the anticipated timing of clinical data readouts. These forward-looking statements are based on Oruka’s current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements except as required by applicable law. 

Investor Contact:

Alan Lada
(650)-606-7911
alan.lada@orukatx.com

NORWOOD, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with a Special Meeting of Stockholders (the “Special Meeting”) to seek stockholder approval of a proposed reverse stock split of the Company’s common stock (the “Reverse Stock Split”).

The proposed Reverse Stock Split is intended to provide MariMed with greater flexibility to satisfy the minimum share price and other requirements associated with a potential listing of its common stock on a U.S. national securities exchange. If the proposal is approved by the Company’s stockholders, the Reverse Stock Split will be effected in the sole discretion of the Board of Directors (the “Board”).

“Our Board believes that positioning MariMed to pursue a listing on a major U.S. exchange is an important step in the Company’s evolution,” said Jon Levine, Chief Executive Officer of MariMed. “A national exchange listing has the potential to broaden our investor base by increasing the Company’s visibility among institutional investors, research analysts and broker-dealers and improve access to the capital markets. As the regulatory environment for the cannabis industry as well as the capital markets continue to evolve, we believe taking these steps now gives us greater strategic flexibility.”

There can be no assurance that the Board will determine to effect the Reverse Stock Split, that MariMed will be eligible for listing on a U.S. national securities exchange, that the Reverse Stock Split will enable the Company to satisfy all applicable listing requirements, or that the Reverse Stock Split will result in a sustained increase in the trading price or liquidity of the Company’s common stock.

Reverse Stock Split Details

If approved by stockholders:

• The Reverse Stock Split proposal would authorize the Board to determine whether and when to implement the Reverse Stock Split at a ratio of between one for fifty and one for one-hundred, in its discretion. The Board would determine the final ratio based on market conditions and other relevant considerations, including the requirements associated with a potential listing of the Company’s common stock on a U.S. national securities exchange.
• The Board would retain the discretion not to implement the Reverse Stock Split if it determines that doing so would not be in the best interests of the Company and its stockholders.

• No fractional shares would be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split will instead receive a cash payment in lieu of such fractional share.

If the Reverse Stock Split is implemented:

• The number of shares of MariMed common stock outstanding would be reduced by the applicable split ratio. The Reverse Stock Split would not, by itself, change a stockholder’s proportional ownership or voting power in the Company, except for any adjustments resulting from the treatment of fractional shares.

Special Meeting of Stockholders

The Special Meeting is scheduled to be held virtually on October 28, 2026 at 9:30 am eastern time, or a later date if adjourned. Stockholders of record as of the close of business on September 4, 2026 will be entitled to vote on the Reverse Stock Split proposal at the Special Meeting.

The definitive proxy statement has been filed with the SEC and is available through the SEC’s website and on MariMed’s Investor Relations website. Stockholders are encouraged to read the definitive proxy statement in its entirety because it contains important information regarding the Reverse Stock Split proposal, including the reasons for the proposal and associated risks.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in connection with the proposal to be submitted to the Company’s stockholders at the Special Meeting seeking approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split (the “Reverse Stock Split Proposal”). This communication does not contain all the information that should be considered concerning the Reverse Stock Split Proposal and is not intended to form the basis of any investment decision or any other decision in respect of the Reverse Stock Split Proposal. In connection with the Special Meeting, the Company filed a definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on September 22, 2026. The Company’s stockholders are urged to read the definitive proxy statement and all other relevant materials filed with the SEC as such documents contain important information about the Company, the Special Meeting and the Reverse Stock Split Proposal. The definitive proxy statement and other relevant materials are being made available to the Company’s stockholders as of the record date for the Special Meeting and may be obtained free of charge at the SEC’s website, www.sec.gov, or via the Company’s website, www.marimedinc.com.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the Reverse Stock Split Proposal. Information about the Company’s directors and executive officers, including a description of their direct or indirect interests in the Reverse Stock Split Proposal, is set forth in the definitive proxy statement for the Special Meeting filed with the SEC on September 22, 2026. The definitive proxy statement may be obtained free of charge from the sources indicated above.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Important Caution Regarding Forward-Looking Statements
The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without limitation statements regarding the proposed listing of the Company’s common stock on a national exchange and the affect and impact of the Reverse Split are forward-looking statements. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “expectations,” “intends,” “may,” “plans,” and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on the Company’s current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, its ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect the Company’s business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in the Company’s reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

For More Information Contact:

Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — On September 22, 2026, the Board of Directors of AGF Management Limited declared a dividend of 13.5 cents per share on both the Class B Non-Voting shares and the Class A Voting common shares of the company. This dividend will be payable on October 15, 2026 to shareholders of record on October 1, 2026.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.

AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and alternative investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.

Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. With over $74 billion in total assets under management and fee-earning assets, AGF serves more than 820,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

AGF Management Limited shareholders, analysts and media, please contact:

Nick Smerek
VP, Financial Planning & Analysis
416-865-4337, InvestorRelations@agf.com

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) —

• Reported quarterly adjusted diluted earnings per share of $0.49
• Free cash flows of $38.9 million in the quarter, up 27% from prior year
• Total assets under management and fee-earning assets of $74.2 billion, up 31% from prior year
• Declared quarterly dividend per share of 13.5 cents

AGF Management Limited (AGF or the Company) (TSX: AGF.B) today announced financial results for the third quarter ended August 31, 2026.

AGF reported total assets under management and fee-earning assets¹ of $74.2 billion compared to $74.7 billion in the prior period and $56.8 billion in the comparative prior year period. AGF generated strong free cash flows of $38.9 million in the quarter, up 27% from the prior year.

“We are pleased with the progress we have made through the first three quarters of the year. Our teams continue to execute against our strategic priorities, strengthen our business and deepen relationships with clients and partners,” said Judy Goldring, Chief Executive Officer, AGF Management Limited.

AGF Investments’ mutual fund gross sales were $1,366 million for the quarter compared to $1,363 million in the prior period and $1,260 million in the comparative prior year period. Canadian retail net flows² were $271.0 million for the quarter, compared to $161.0 million in the prior period and $309.0 million in the comparative prior year period.

“As we look ahead, we remain committed to our strategy and focused on the long term. We are building on our strong foundation, continuing to expand our capabilities and pursuing opportunities to drive growth. With a strong team, differentiated investment capabilities and a clear sense of where we are going, we are well positioned to continue creating value for our clients and shareholders,” added Goldring.

_{¹ AUM represents assets under management and model delivery assets of AGF subsidiaries and affiliates. Fee-earning assets represents assets managed by affiliates in which AGF has carried interest ownership and earns fees but does not have ownership interest in the managers.
² Canadian retail net flows includes Canadian retail mutual fund net sales and Canadian ETF and SMA net sales.}

Key Business Highlights:

AGF Investments

AGF Investments launched ETF series units for the AGF Enhanced U.S. Income Plus Fund (AENP), expanding the firm’s ETF lineup and providing investors with greater choice.

AGF Investments also continued to see strong demand across its ETF and separately managed account (SMA) offerings, reflecting growing interest in flexible investment solutions. During the quarter, the AGF U.S. Large Cap Growth Strategy was added to a leading U.S. advisory platform, further expanding SMA access and broadening the firm’s reach in the U.S. market.

AGF Capital Partners

In July, following an extensive global search, Kensington Capital Partners Limited, an affiliate manager of AGF Capital Partners, appointed industry veterans Saar Pikar and Bogdan Cenanovic to its senior leadership team, strengthening its depth and expertise to support the firm’s next phase of growth.

Financial Highlights:

• Adjusted EBITDA³ for the three months ended August 31, 2026 was $48.8 million, compared to $64.1 million for the three months ended May 31, 2026 and $46.2 million for the comparative prior year period.
• Net management, advisory and administration fees³ for the three months ended August 31, 2026 was $101.0 million, compared to $96.7 million for the three months ended May 31, 2026 and $88.8 million for the comparative prior year period.
• Adjusted selling, general and administrative costs³ for the three months ended August 31, 2026 was $63.7 million, compared to $62.6 million for the three months ended May 31, 2026 and $61.3 million for the comparative prior year period. Adjusted SG&A increased compared to the prior period and comparative prior year period, primarily driven by higher non-compensation expenses.
• Adjusted EBITDA³ from AGF Capital Partners for the three months ended August 31, 2026, was $8.5 million, compared to $21.5 million for the three months ended May 31, 2026 and $11.4 million for the comparative prior year period. The decrease over the prior period is primarily due to lower revenue from long-term investments and a $14.7 million gain recognized on the NHC transaction in the prior period.
• Adjusted EBITDA³ excluding AGF Capital Partners of $40.3 million for the three months ended August 31, 2026, compared to $42.6 million for the three months ended May 31, 2026 and $34.8 million for the comparative prior year period.
• Adjusted net income attributable to equity owners³ for the three months ended August 31, 2026 was $32.0 million ($0.49 adjusted diluted EPS), compared to $46.9 million ($0.72 adjusted diluted EPS) for the three months ended May 31, 2026 and $31.2 million ($0.46 adjusted diluted EPS) for the comparative prior year period.
• Free cash flow³ of $38.9 million for the three months ended August 31, 2026, compared to $36.4 million for the three months ended May 31, 2026 and $30.6 million for the comparative prior year period.

		Three months ended												Nine months ended
			August 31,				May 31,				August 31,				August 31,				August 31,
	(in millions of Canadian dollars, except per share data)		2026				2026				2025				2026				2025
	Revenues
	Management, advisory and administration fees	$	141.7			$	135.8			$	126.7			$	408.4			$	369.0
	Trailing commissions and investment advisory fees		(40.7	)			(39.1	)			(37.9	)			(118.3	)			(111.2	)
	Net management, advisory and administration fees3	$	101.0			$	96.7			$	88.8			$	290.1			$	257.8
	Deferred sales charges		0.6				0.8				0.9				2.3				3.1
	Adjusted revenue from AGF Capital Partners3		10.9				26.6				15.5				38.3				53.7
	Other revenue3		–				2.6				2.3				3.8				3.4
	Total adjusted net revenue3		112.5				126.7				107.5				334.5				318.0
	Selling, general and administrative		64.8				64.0				65.9				196.3				196.6
	Adjusted selling, general and administrative3		63.7				62.6				61.3				191.4				184.4
	EBITDA3		47.4				63.0				42.1				138.7				122.5
	EBITDA margin3		42.1%				49.7%				39.2%				41.4%				38.5%
	Adjusted EBITDA3		48.8				64.1				46.2				143.1				133.6
	Adjusted EBITDA margin3		43.4%				50.6%				43.0%				42.8%				42.0%
	Net income – equity owners of the Company		31.2				46.3				28.4				95.6				83.6
	Adjusted net income – equity owners of the Company3		32.0				46.9				31.2				98.6				89.3
	Diluted earnings per share		0.48				0.71				0.42				1.46				1.24
	Adjusted diluted earnings per share3		0.49				0.72				0.46				1.50				1.33
	Free cash flow3		38.9				36.4				30.6				111.2				86.2
	Dividends paid per share		0.135				0.135				0.125				0.395				0.365

_{³ Net management, advisory and administration fees, adjusted revenue from AGF Capital Partners, total adjusted net revenue, adjusted selling, general and administrative, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted diluted earnings per share and free cash flow are not standardized measures prescribed by IFRS. The Company utilizes non-IFRS measures to assess our overall performance and facilitate a comparison of quarterly and full-year results from period to period. They allow us to assess our investment management business without the impact of non-operational items. These non-IFRS measures may not be comparable with similar measures presented by other companies. These non-IFRS measures and reconciliations to IFRS, where necessary, are included in the Management’s Discussion and Analysis available at www.agf.com.}

		Three months ended
			August 31,				May 31,			February 28,			November 30,			August 31,
	(in millions of Canadian dollars)		2026				2026			2026			2025			2025
	Mutual fund AUM4	$	37,529			$	37,985		$	35,817		$	34,984		$	32,958
	ETFs and SMA AUM5		5,481				4,823			4,492			4,136			3,487
	Segregated accounts and sub-advisory AUM		5,874				6,634			5,923			7,190			6,685
	Total AGF Investments AUM		48,884				49,442			46,232			46,310			43,130
	AGF Private Wealth AUM		9,685				9,948			9,764			9,488			9,016
	AGF Capital Partners AUM6		13,533				13,178			2,345			2,454			2,510
	Total AUM	$	72,102			$	72,568		$	58,341		$	58,252		$	54,656
	AGF Capital Partners fee-earning assets7		2,133				2,129			2,120			2,136			2,121
	Total AUM and fee-earning assets7	$	74,235			$	74,697		$	60,461		$	60,388		$	56,777
	Mutual fund net sales (redemptions)		(30	)			6			190			276			247
	Canadian retail net flows2		271				161			431			488			309
	Canadian retail mutual fund net sales8		92				6			237			282			262
	Canadian ETF and SMA net sales5		179				155			194			206			47
	Average daily mutual fund AUM		38,045				35,869			35,154			34,424			32,122

_{⁴ Mutual fund AUM includes retail AUM, pooled funds AUM and institutional client AUM invested in customized series offered within mutual funds.
⁵ ETF and SMA AUM includes model delivery assets – third-party managed account assets for which AGF provides model portfolios and earns a model delivery fee, without custody or discretionary management of the underlying accounts.
⁶ AGF Capital Partners AUM represents the total assets under management of the Affiliate Managers that comprise AGF Capital Partners. This includes the full AUM of Affiliate Managers for which AGF consolidates or uses the equity method of accounting.
⁷ Fee-earning assets represents assets managed by affiliates in which AGF has carried interest ownership and earns fees but does not have ownership interest in the managers.
⁸ Net sales in retail mutual funds is calculated as reported mutual fund net sales (redemptions) less non-recurring institutional net sales (redemptions) in excess of $5.0 million invested in our mutual funds.}

For further information and detailed financial statements for the third quarter ended August 31, 2026, including Management’s Discussion and Analysis, which contains discussions of non-IFRS measures, please refer to AGF’s website at www.agf.com under ‘About AGF’ and ‘Investor Relations’ and at www.sedarplus.ca.

Conference Call

AGF will host a conference call to review its earnings results today at 11 a.m. ET.

The live audio webcast with supporting materials will be available in the Investor Relations section of AGF’s website at www.agf.com or at https://edge.media-server.com/mmc/p/iksbp2qy. Alternatively, the call can be accessed over the phone by registering here or in the Investor Relations section of AGF’s website at www.agf.com, to receive the dial-in numbers and unique PIN.

A complete archive of this discussion along with supporting materials will be available at the same webcast address within 24 hours of the end of the conference call.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.
 
AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and alternative investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.
 
Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. With over $74 billion in total assets under management and fee-earning assets, AGF serves more than 820,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

About AGF Investments

AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). The term AGF Investments may refer to one or more of these subsidiaries or to all of them jointly. This term is used for convenience and does not precisely describe any of the separate companies, each of which manages its own affairs. AGF Investments entities only provide investment advisory services or offers investment funds in the jurisdiction where such firm and/or product is registered or authorized to provide such services.

About AGF Capital Partners

AGF Capital Partners is AGF’s multi-boutique alternatives business with Affiliate Managers across both private assets and alternative strategies. Clients benefit from the specialized investment expertise of Affiliate Managers combined with the organizational support and breadth of resources of AGF Management Limited (AGF). With over 19 years average experience, AGF Capital Partners Affiliate Managers including, Kensington Capital Partners Limited, New Holland Capital, LLC and AGF SAF Private Credit, manage approximately C$15.7 billion* in alternative AUM and fee earning assets on behalf of institutional and retail clients.

 *U.S. AUM converted FX rate as at August 31, 2026 (1.39)

The term ‘Affiliate Manager’ refers to any partner regardless of relationship structures or revenue sharing agreements. The form of AGF’s structured partnership interests in Affiliate Managers differs from Affiliate Manager to Affiliate Manager. The structure of the relationship with a particular Affiliate Manager, or the revenue that AGF agrees to share in, may change. Affiliate Managers only provide investment advisory services or offer products in the jurisdiction where such firm, individuals and/or product is registered or authorized to provide such services.

Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated.

AGF Management Limited shareholders, analysts and media, please contact:

Nick Smerek
VP, Financial Planning & Analysis
416-865-4337, InvestorRelations@agf.com

Caution Regarding Forward-Looking Statements

This press release includes forward-looking statements about the Company, including its business operations, strategy and expected financial performance and condition. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as ‘expects,’ ‘estimates,’ ‘anticipates,’ ‘intends,’ ‘plans,’ ‘believes’ or negative versions thereof and similar expressions, or future or conditional verbs such as ‘may,’ ‘will,’ ‘should,’ ‘would’ and ‘could.’ In addition, any statement that may be made concerning future financial performance (including income, revenues, earnings or growth rates), ongoing business strategies or prospects, fund performance, and possible future action on our part, is also a forward-looking statement. Forward-looking statements are based on certain factors and assumptions, including expected growth, results of operations, business prospects, business performance and opportunities. While we consider these factors and assumptions to be reasonable based on information currently available, they may prove to be incorrect. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about our operations, economic factors and the financial services industry generally. They are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied by forward-looking statements made by us due to, but not limited to, important risk factors such as level of assets under our management, volume of sales and redemptions of our investment products, performance of our investment funds and of our investment managers and advisors, client-driven asset allocation decisions, pipeline, competitive fee levels for investment management products and administration, and competitive dealer compensation levels and cost efficiency in our investment management operations, as well as general economic, political and market factors in North America and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, taxation, changes in government regulations, unexpected judicial or regulatory proceedings, technological changes, cybersecurity, the possible effects of war or terrorist activities, outbreaks of disease or illness that affect local, national or international economies, natural disasters and disruptions to public infrastructure, such as transportation, communications, power or water supply or other catastrophic events, and our ability to complete strategic transactions and integrate acquisitions, and attract and retain key personnel. We caution that the foregoing list is not exhaustive. The reader is cautioned to consider these and other factors carefully and not place undue reliance on forward-looking statements. Other than specifically required by applicable laws, we are under no obligation (and expressly disclaim any such obligation) to update or alter the forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete discussion of the risk factors that may impact actual results, please refer to the ‘Risk Factors and Management of Risk’ section of the 2025 Annual MD&A.

CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial results for the third quarter ending on September 30, 2026, before the market opens on Thursday, October 29, 2026.

A conference call and webcast with analysts and investors is scheduled for October 29, 2026, at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results.

• Investors and participants can register in advance for the call by visiting: https://register-conf.media-server.com/register/BI10964a36c81a483c80c6a571ef0f9518
• After registering, instructions will be shared on how to join the call for those who wish to dial in.
• On October 29, the live webcast can be accessed via the following link: https://edge.media-server.com/mmc/p/mr3yjhvp
• The live and archived webcast will be available on the Events and Presentations page of the Company’s investor relations website at investors.verano.com.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf^™ and MÜV^™ dispensary banners, and produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Savvy^™, (the) Essence^™, Swift Lifts^™, HYPHEN^™, Encore^™, Easy Landings^™, BITS^™, Avexia^™, MÜV^™, CTPharma^™, and Verano^™. Verano’s active operations span 13 U.S. states, comprised of 14 production facilities with over 1.1 million square feet of cultivation capacity. Learn more at Verano.com.

Contacts:
Investors
Verano
Aaron Miles
Chief Investment Officer
Investors@verano.com

Media
Verano
Steve Mazeika
Vice President, Communications
steve.mazeika@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

##